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The discoidin domain receptors, DDR1 
and DDR2, are receptor tyrosine kinases that 
are activated by native triple-helical collagen. 
Here we have located three specific DDR2 
binding sites by screening the entire triple-
helical domain of collagen II, using the 
Collagen II Toolkit, a set of overlapping 
triple-helical peptides. The peptide sequence 
that bound DDR2 with highest affinity 
interestingly contained the sequence for the 
high-affinity binding site for von Willebrand 
factor in collagen III. Focussing on this 
sequence, we used a set of truncated and 
alanine-substituted peptides to characterise 
the sequence GVMGFO (O is 
hydroxyproline) as the minimal collagen 
sequence required for DDR2 binding. Based 
on a recent NMR analysis of the DDR2 
collagen-binding domain, we generated a 
model of the DDR2-collagen interaction that 
explains why a triple-helical conformation is 
required for binding. Triple-helical peptides 
comprising the DDR2 binding motif not only 
inhibited DDR2 binding to collagen II, but 
also activated DDR2 transmembrane 
signalling. Thus, DDR2 activation may be  
effected by single triple-helices rather than 
fibrillar collagen.  
The mammalian discoidin domain receptors 
(DDRs), DDR1 and DDR2, are receptor tyrosine 
kinases (RTKs) that function as collagen 
receptors (1,2). Several collagen types, in 
particular fibrillar collagens, bind to and activate 
the DDRs, with the two receptors displaying 
different specificities towards certain collagen 
types (3,4). DDR activation by collagen is 
strictly dependent on the native, triple-helical 
conformation of collagen (1,2,5). The DDRs are 
unique among RTKs in being activated by a 
component of the extracellular matrix; most 
RTKs are activated by small diffusible proteins 
such as growth factors. Like conventional RTKs, 
the DDRs regulate fundamental cellular 
processes including cell proliferation, adhesion, 
and migration, but the DDRs additionally 
control remodelling of the extracellular matrix 
(6-9). Both receptors control developmental 
processes, such as mammary gland development 
(DDR1) (10) and the growth of long bones 
(DDR2) (11), and are associated with human 
diseases, including fibrotic diseases of the liver, 
kidney and lung, atherosclerosis, osteoarthritis 
and several types of cancer (reviewed in ref 12). 
The homologous DDRs are composed of an 
N-terminal discoidin homology (DS) domain, 
followed by a stalk region unique to DDRs 
(~220 amino acids), a transmembrane domain, a 
large cytosolic juxtamembrane domain and a C-
terminal tyrosine kinase domain (13). DDR 
activation, manifested by autophosphorylation, 
is a consequence of collagen binding to a 
specific site in the DS domain (5,14). Collagen-
induced DDR autophosphorylation is unusually 
slow and sustained (1,2), compared with the 
rapid response of canonical RTKs to their 
ligands.  
Collagens form a large protein family that is 
characterised by repeating glycine-X-X' 
sequences, where X and X' are often proline and 
4-hydroxyproline, respectively (15). Three 
collagen chains form a right-handed triple-
helical structure. The fibrillar collagens (types I, 
II, III, V and XI) are characterised by triple-
helical domains of ~1000 amino acids that self-
assemble into highly organised fibrils, and play 
key architectural roles in connective tissues. 
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The interactions of fibrillar collagens with 
some of their cellular receptors, in particular 
integrins, have been well characterised. 
Collagen-binding integrins recognise discrete 
amino acid sequences in triple-helical collagen. 
The use of synthetic triple-helical peptides 
allowed the identification of an important, high-
affinity integrin-binding site, GFOGER (where 
O is hydroxy-proline) (16,17), which is present 
in a number of different collagens, including 
collagens I and II. In contrast to the collagen-
binding integrins, for which a receptor-ligand 
co-crystal has been described as a complex 
between the alpha-2 I domain and the model 
collagen peptide GFOGER (18), we know little 
about the molecular mechanism by which the 
DDRs recognise collagen. Our previous work 
showed that DDR2 binds to a specific site within 
the D2 period of collagen II (3), but the nature of 
this (or, indeed, any other) DDR2 binding motif 
is unknown. 
In the present study, we have characterised 
DDR2 binding motifs in collagen, using the 
collagen II Toolkit, a set of 56 overlapping 
triple-helical peptides encompassing the entire 
triple-helical domain of human collagen II. The 
Toolkit approach allows a comprehensive 
analysis of binding sites within a fibrillar 
collagen type. We previously used the collagen 
III Toolkit to locate novel binding sites for 
integrins and von Willebrand factor (VWF) in 
human collagen III (19,20). Screening the 
collagen II Toolkit for binding to recombinant 
DDR2 identified three major binding sites. 
Coincidentally, one of the binding sites is almost 
identical to the recently identified high-affinity 
binding site for VWF in collagens II and III (20). 
Focussing on this peptide sequence, we used a 
set of truncated and alanine-substituted peptides 
to characterise the minimal collagen sequence 
required for DDR2 binding. The specific amino 
acid motif recognised by DDR2 is distinct from 
that of integrins and the platelet collagen 
receptor glycoprotein VI (GpVI) (21). 
Importantly, triple-helical peptides comprising 
the DDR2 binding site not only inhibited DDR2 
binding to collagen II, but were able to activate 
DDR2 autophosphorylation in a specific manner. 
 
Experimental Procedures 
 
Peptide synthesis – The sequences of the 
peptides used in this study are shown in 
Supplementary Table 1 and in Table 1. Peptides 
were synthesised by Fmoc (N-(9-
fluorenyl)methoxycarbonyl) chemistry as C-
terminal amides on TentaGel R RAM resin in an 
Applied Biosystems Pioneer automated 
synthesiser and purified as described (19). All 
peptides were verified by mass spectrometry and 
shown to adopt triple-helical conformation by 
polarimetry (Slatter et al, submitted). 
Chemicals and reagents – BSA was 
obtained from Fisher Scientific, Loughborough, 
UK. Collagen I (acid-soluble from rat tail, C-
7661) and collagen IV (acid-soluble from 
placenta; C-5533) were purchased from Sigma 
(Poole, UK). Bovine collagen II, ELISA grade, 
was from Chondrex Inc. (Redmond, WA). The 
antibodies and their sources were as follows: 
anti-DDR2, goat anti-DDR2 Ig (AFA2538) from 
R&D Systems (Abingdon, UK); mouse anti-Myc 
tag, clone 9E10, from Upstate (Lake Placid, 
NY); peroxidase-conjugated goat anti-human Fc 
from Jackson ImmunoResearch Laboratories 
(West Grove, PA); anti-phosphotyrosine, clone 
4G10, from Upstate. Secondary antibodies were 
as follows: sheep anti-mouse Ig-horseradish 
peroxidase (Amersham Biosciences UK, 
Chalfont St Giles, UK); rabbit-anti-goat Ig-
horseradish peroxidase (Zymed Laboratories, 
San Francisco, CA). 
Cell culture and cell lines – Human 
embryonic kidney (HEK) 293 cells (ATCC, 
Manassas, VA), HEK293-EBNA cells 
(Invitrogen Ltd, Paisley, UK), and HEK293-T 
cells (ATCC) were cultured in Dulbecco’s 
modified Eagle medium (DMEM)/F12 nutrient 
mixture (Invitrogen, UK) with 10% fetal bovine 
serum. 
Production and purification of recombinant 
proteins – The production and purification of 
recombinant DDR proteins was as previously 
described (5). The His-tagged DDR2 
extracellular domain protein (His-DDR2) was 
produced from episomally transfected HEK293-
EBNA cells. The Fc-tagged DDR2 DS domain 
(DS2-Fc) was isolated from episomally 
transfected HEK293-T cells. 
Solid-phase collagen binding assays – The 
assay procedure has been described previously 
in detail (5). Briefly, collagens or collagen 
peptides were diluted in 0.01 M acetic acid to 10 
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µg/ml and coated onto Immulon 2 HB 96-well 
plates (Fisher Scientific) overnight at room 
temperature. This represents a 10-fold excess 
over saturating concentration of peptide, verified 
using similar peptides for integrin and platelet 
binding (D.J. Onley, PhD Thesis, University of 
Cambridge 2001). Wells were then blocked for 1 
h at room temperature with 1 mg/ml BSA in 
PBS plus 0.05% Tween-20 (PBS-T). 
Recombinant DDR2 proteins, diluted in 
incubation buffer (0.5 mg/ml BSA in PBS-T) 
were added for 3 h at room temperature. Wells 
were washed 6 times with incubation buffer 
between all incubation steps. Bound His-DDR2 
protein was detected with anti-Myc monoclonal 
antibody (1:1000 dilution), added for 1 h at 
room temperature, followed by sheep anti-mouse 
horseradish peroxidase (1:1000 dilution), added 
for 1 h at room temperature. Bound DS2-Fc 
protein was detected with goat anti-human Fc 
coupled to horseradish peroxidase (1:3333 
dilution), added for 1 h at room temperature. A 
colour reaction was subsequently performed 
using o-phenylenediamine dihydrochloride 
(Sigma), added for 3-5 min. The reaction was 
stopped with 3 M H2SO4, and plates were read in 
an ELISA assay reader at 492 nm. For the 
blocking assays, His-DDR2 was pre-incubated 
with the indicated concentrations of peptides for 
1 h at room temperature prior to adding of the 
His-DDR2/peptide mixture to collagen II coated 
plates. The assay was developed as described 
above.  
Collagen-induced DDR 
autophosphorylation – The assay was performed 
as previously described in detail (5). Briefly, 
HEK293 cells in 24-well plates were transfected 
by calcium phosphate precipitation with DDR2 
expression vector (5). 24 h later, the cells were 
incubated with serum-free medium for 16 h. 
Cells were then stimulated with collagen I, 
collagen II (both at 10 µg/ml), or different 
collagen peptides (at 100 µg/ml) for 90 min, or 
as indicated, at 37°C. Cells were lysed in 1% 
Nonidet P-40, 150 mM NaCl, 50 mM Tris, pH 
7.4, 1 mM EDTA, 1 mM phenylmethylsulfonyl 
fluoride, 50 µg/ml aprotinin, 1 mM sodium 
orthovanadate, 5 mM NaF. Aliquots of the 
lysates were analysed by SDS-PAGE, followed 
by blotting onto nitrocellulose membranes. The 
blots were probed with mouse anti-
phosphotyrosine mAbs, followed by sheep anti-
mouse Ig horseradish peroxidase. Detection was 
by enhanced chemiluminescence (Amersham 
Biosciences). To strip the blots, membranes 
were incubated in Antibody stripping solution 
(Alpha Diagnostic International, San Antonio, 
Texas) for 10 min at room temperature. The 
blots were reprobed with goat anti-DDR2 Abs, 
followed by rabbit anti-goat Ig-horseradish 
peroxidase. 
 
RESULTS 
 
The collagen II Toolkit – Sequences of 
collagen II Toolkit peptides are shown in 
Supplementary Table 1. The host-guest strategy 
(22) was applied, as in our previous studies 
(16,23), where the guest (primary) sequence of 
interest is placed between (GPP)5 hosts, inert 
flanking sequences which impart triple-helical 
conformation on the whole peptide. Each 
Toolkit peptide contains a guest sequence of 27 
amino acids, the C-terminal 9 amino acids of 
which form the first 9 guest amino acids of the 
next peptide. Thus, the guest sequence of the 
Toolkit advances 18 amino acids along the 
triple-helical domain of collagen II with each 
successive peptide, and a 9 amino acid overlap is 
included between adjacent peptides. 
Mapping DDR2 binding sites within 
collagen II – Our previous studies used two 
recombinant soluble extracellular DDR2 
proteins to analyse the binding of DDR2 to 
immobilised collagen ligands (3-5): one 
construct comprising the entire DDR2 
extracellular domain, N-terminally tagged with a 
His-tag and a Myc epitope (His-DDR2), the 
other construct consisting mainly of the DDR2 
DS domain, C-terminally tagged with an Fc-tag 
(DS2-Fc). Both of these constructs exhibited 
high-affinity binding to the fibrillar collagens I 
and II, but, like full-length DDR2, did not 
recognise the basement membrane collagen IV. 
In this study, we used the same recombinant 
DDR2 proteins and screened the collagen II 
Toolkit peptides for DDR2 binding (Figure 1). 
Both DDR2 proteins showed good binding to 
only four peptides: Toolkit peptides II-13, II-22, 
II-23, and II-44. The response was similar to (or 
greater than) that to full-length immobilised 
collagen II. However, this might be an 
overestimation, as the peptides likely immobilise 
at greater molar concentration on the plates due 
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to their lower molecular weight compared to 
full-length collagen II. There was no binding, as 
expected, to collagen IV or BSA. In addition, the 
control peptide GPP, [GPC-(GPP)10-GPC-NH2], 
which consists entirely of the peptide ‘host’ 
sequence, was not recognised. Similarly, peptide 
CRP, [GPC-(GPO)10-GPC-NH2], a ligand for the 
platelet collagen receptor GpVI (24), did not 
interact with DDR2. In addition to the four 
strongly interacting peptides, His-DDR2 showed 
above background binding to three further 
peptides, II-17, II-38 and II-39. 
Solid phase binding assays showed that the 
DDR2 proteins had highest affinity to 
immobilised peptide II-22, amongst the four 
positive peptides identified in the screen. Half 
maximal binding occurred at ~10 nM added 
DDR2 proteins (Figure 2). 
Identification of the minimal collagen 
sequence required for DDR2 binding – As the 
Toolkit is a set of overlapping peptides, it was 
likely that DDR2 recognised the overlapping 
sequence of peptides II-22 and II-23. Inspection 
of the overlap sequence revealed, interestingly, 
that this sequence (GQOGVMGFO) is almost 
identical to the recently identified high-affinity 
binding site for VWF in collagen III 
(RGQOGVMGFO) (20). In this previous work, 
we screened the entire collagen III Toolkit for 
VWF binding and identified a single peptide, III-
23, that bound plasma VWF. We tested this 
peptide and a set of truncated and alanine-
substituted peptides derived from this sequence 
(see Table 1) for DDR2 binding (Figure 3A and 
Supplementary Figure 1A). The response of both 
DDR2 proteins to III-23 was similar to their 
response to II-22. The results of the truncated 
peptide series showed that DDR2 bound strongly 
to the peptide sequence GVMGFO at 10 µg/ml 
(142 nM) DDR2, but did not bind any peptides 
in which this hexapeptide sequence was 
truncated; this hexapeptide will therefore be 
referred to as the minimal binding sequence. 
However, at lower DDR2 protein concentrations 
(2 µg/ml, 28 nM), both GVMGFO and the 
longer sequence GQOGVMGFO gave sub-
optimal responses, indicating that these peptides 
are recognised with lower affinity. Extending the 
sequence by a further amino acid triplet to 
GPRGQOGVMGFO gave optimal responses for 
both DDR2 concentrations. Dose response 
curves for both GPRGQOGVMGFO and 
GPSGPRGQOGVMGFO showed that DDR2 
recognised these peptides with similar high 
affinity that was even somewhat greater than the 
affinity with which DDR2 recognised Collagen 
II Toolkit peptide, II-22 (Supplementary Figure 
2). 
DDR2 binding to intact collagen is strictly 
dependent on the native triple-helical 
conformation. It was therefore important to test 
whether DDR2 would recognise a non-helical 
collagen peptide. A non-helical version  (GAP-
GPR-GFO; see Table 1) of the high-affinity 
DDR2 ligand GPRGQOGVMGFO, was non-
helical above 8°C as determined by polarimetry 
(data not shown), and supported no binding by 
DDR2 (Figure 3A, Supplementary Figure 1A 
and Supplementary Figure 2), indicating that 
peptide recognition by DDR2 in our system 
mirrors recognition of native collagen by DDR2. 
Moreover, DDR2 did not recognise GFOGER, 
the high-affinity integrin binding site identified 
previously by us (16). Alanine scanning showed 
that two amino acids, M and F, are crucial for 
DDR2 recognition; substitution of R and O 
(underlined in GPRGQOGVMGFO) led to a 
modest reduction in binding, whereas all other X 
and X’ positions could be substituted with no 
apparent loss of binding (Figure 3B and 
Supplementary Figure 1B).  
In human collagen I, a heterotrimer of two 
α1 and one α2 chains, a related sequence occurs 
in the α1 chain (GARGQAGVMGFO) that 
differs in two amino acids from the high-affinity 
DDR2 binding sequence in collagen III (one 
amino acid difference to the motif 
GARGQOGVMGFO in collagen II). As 
expected from the results of the alanine-
substituted peptides, a triple-helical peptide 
comprising this sequence was recognised by 
DDR2, albeit to a somewhat lesser degree at the 
lower protein concentrations tested (Figure 3B 
and Supplementary Figure 1B). The sequence in 
the α2 chain that aligns with this sequence, 
GARGEOGNIGFO, was recognised much less 
well, suggesting that the two α1 chains of 
collagen are the major contributors to the 
corresponding DDR2 binding site in collagen I. 
High-affinity DDR2 binding peptides inhibit 
DDR2 binding to collagen II – We tested 
whether the two high-affinity DDR2 binding 
peptides, GPRGQOGVMGFO and 
GPSGPRGQOGVMGFO, could inhibit DDR2 
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binding to immobilised full-length collagen II. 
Both peptides efficiently inhibited DDR2 
binding with half maximal inhibition at ~50 
µg/ml (~10 µM) (Figure 4). Importantly, the 
non-helical version of GPRGQOGVMGFO did 
not inhibit DDR2 binding. 
Activation of transmembrane signalling by 
high-affinity DDR2 binding peptides – In order 
to relate the binding of triple-helical collagen 
peptides to receptor activation of membrane-
bound DDR2, we expressed full-length DDR2 
transiently in HEK293 cells and examined 
whether the peptides could induce DDR2 
autophosphorylation (Figure 5). Activation by 
collagen peptides required 50-100 µg/ml 
peptides in the medium, compared to 10 µg/ml 
collagen. The reasons for the lower potency of 
the peptides are unclear at present. Importantly, 
however, there was a strict correlation between 
the ability to induce DDR2 autophosphorylation 
and high-affinity DDR2 binding. While peptides 
encompassing the sequence 
GPRGQOGVMGFO activated the receptor, the 
two smaller (lower affinity) peptides GVMGFO 
and GQOGVMGFO did not. Significantly, 
replacing F by A in the context of otherwise 
activating sequence GPSGPRGQOGVMGFO 
abolished DDR2 autophosphorylation. 
Moreover, the non-helical version of 
GPRGQOGVMGFO did not activate DDR2. 
Taken together, these results show that triple-
helical peptides comprising the DDR2 binding 
site activate DDR2 autophosphorylation in a 
specific manner, demonstrating that the 
identified triple-helical motif is a genuine DDR 
agonist leading to transmembrane signalling. 
Collagen-induced DDR autophosphorylation 
occurs with unusually slow and sustained 
kinetics (1,2). Peptide GPRGQOGVMGFO 
induced DDR2 autophosphorylation with the 
same slow kinetics as collagen I, with maximal 
DDR2 phosphorylation detectable at ~60 min of 
incubation (Figure 6). This result indicates that 
slow cellular processes are responsible for the 
delay in receptor activation, rather than 
accessibility of ligand binding sites within 
collagen. 
 
DISCUSSION 
 
A major unresolved question is whether the 
DDRs recognise specific sequence motifs in 
collagen (13). Here we define, for the first time, 
specific binding motifs for DDR2 in collagen. 
Our results show that, like collagen-binding 
integrins, DDR2 recognises discrete amino acid 
motifs in triple-helical collagen. DDR2 binding 
motifs are distinct from those defined for 
integrins (summarised by ref (19) and the 
platelet collagen receptor GpVI (21,24). 
Screening the Collagen II Toolkit for DDR2 
binding identified only four peptides that bound 
DDR2 strongly. The three binding sites 
identified in collagen II each contain a GFO 
triplet, with the F critical and the O important for 
DDR2 binding to the motif contained in the 
overlap of Toolkit peptides II-22 and II-23 
(henceforth referred to as the central DDR2 
binding motif). The presence of GFO is not 
sufficient for DDR2 binding, however: there are 
eight GFO motifs in the human collagen II 
sequence, five of which do not bind DDR2. 
Importantly, one of these GFO triplets is part of 
the integrin-binding motif, GFOGER, which 
DDR2 did not recognise, neither as an isolated 
motif nor in peptide II-28, the Toolkit peptide 
that contains this motif. 
Our previous work identified a major DDR2 
binding site in the D2 period of collagen II 
(amino acids 235-468 of the triple-helical COL 1 
domain, corresponding to residues 366-599 of 
the human collagen II precursor, Swiss-Prot 
entry P02458) (3). The central DDR2 binding 
motif characterised here in detail corresponds to 
amino acids 391-405 of human collagen II, 
corroborating our earlier findings. The other two 
DDR2 binding sites found here, contained in 
Toolkit peptides II-13 and II-44, correspond to 
amino acids 217-243 and 775-801, respectively. 
Deletion of the D1 period of collagen II (amino 
acids 1-234) partially diminished DDR2 binding 
and inhibited DDR2 autophosphorylation (3), 
corresponding well with our present findings for 
peptide II-13. However, our previous work did 
not identify DDR2 binding sites in the D4 period 
of collagen II (amino acids 703-936). 
Of the three DDR2 binding sites in collagen 
II, only the central motif is conserved in 
collagen III (Figure 7). However, sequences 
corresponding to all three binding sites are 
conserved in the α1 chain of collagen I. DDR2 
bound a peptide from the α1 chain of collagen I 
corresponding to the central binding motif 
(Figure 3 and Supplementary Figure 1). This 
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peptide was also able to induce DDR2 
autophosphorylation (data not shown). Together, 
these findings imply that DDR2 recognises 
mainly the α1 chains in collagen I. 
The central binding motif for DDR2 
overlaps with that for VWF in collagen III 
(RGQOGVMGFO). However, the amino acid 
requirements for DDR2 recognition differ 
substantially from those previously identified for 
VWF recognition (20) (for summary see Figure 
7). While F is crucial for both DDR2 and VWF, 
the latter has an absolute requirement for R (only 
partially required for DDR2), the first O and V 
(neither required for DDR2), while DDR2 
requires M, which is not required for VWF 
binding. This overlap of binding sites within 
collagens suggests that ligands may compete for 
collagen exposed during trauma or disease. It is 
plausible that plasma-borne VWF may inhibit 
the DDR2-collagen interaction, thus restricting 
the activation of DDR2-expressing cells to sites 
remote from the circulation. 
The minimum collagen sequence that bound 
DDR2 comprised six amino acids, GVMGFO, 
like the canonical GXX’GEX” motif recognised 
by integrin I domains (16,19,25-27). F and M 
were found to be critical for the interaction of 
DDR2 with the GVMGFO motif. While this 
manuscript was in preparation, the solution 
structure of the DDR2 DS domain was reported 
and the collagen-binding site mapped by 
transferred cross-saturation and mutagenesis 
experiments (14). The binding site is created by 
surface-exposed loops that form a trench suitable 
to accommodate the collagen triple helix (Figure 
8). The length of this trench spans two to three 
triplets in collagen, in good agreement with our 
results. The residues making up the trench 
include charged amino acids, as well as a 
number of polar and apolar residues. The most 
striking feature is a solvent-exposed aromatic 
residue, W52, whose mutation to alanine 
essentially abrogated collagen II binding (14). 
To gain insight into the mode of collagen 
binding to the DDR2 DS domain, we created a 
molecular model of the DDR2-binding sequence 
GPRGQOGVMGFOGPK based on a (GPO)n 
backbone of 10/3 helical symmetry (Figure 8). 
From this model, it is immediately evident why 
a single polypeptide chain does not bind to 
DDR2: the critical M and F side chains project 
from opposite sides of the chain and cannot 
interact simultaneously with the trench on the 
DS domain. In the triple helix, however, M and 
F side chains from different chains come into 
close proximity, and we propose that one of the 
apolar patches thus formed is accommodated by 
the hydrophobic region of the DS domain trench, 
in particular by the critical side chain of W52 
and the C73-C177 disulphide bond at the floor 
of the trench. Because of the stagger between 
individual chains of a collagen triple helix, there 
exist two different arrangements of M and F side 
chains: one type occurs only once per triple helix 
and involves F of the leading strand and M of 
the trailing strand (facing left in Figure 8); the 
second type occurs twice and involves M from 
the leading or middle strand and F from the 
middle or trailing strand, respectively (facing 
right and to the back in Figure 8). We used 
manual and computational docking to see 
whether one of these types led to a preferred 
mode of binding (data not shown). However, 
both types could be accommodated equally well, 
with either M or F (or possibly O) stacking 
against W52. Whether this uncertainty is due to 
the limitations of the docking routines (we did 
not attempt to model conformational changes in 
the DS domain) or an inherent feature of the 
DDR2-collagen interaction remains to be seen. 
A unique binding mode may be imposed by 
interactions outside the core GVMGFO motif in 
collagen. Indeed, our data show that the arginine 
residue upstream of the hydrophobic motif 
contributes to binding and DDR2 activation. In a 
subset of our docking models, this arginine can 
be oriented to make an electrostatic interaction 
with E113, which has been implicated in 
collagen binding (14). Further structural studies 
will be required to define the atomic details of 
the DDR2-collagen interaction. 
DDR2 has the same overall architecture as 
the homologous DDR1. The DS domains of the 
DDRs share an overall sequence identity of 
59%, but the surface-exposed loops comprising 
the collagen binding site of DDR2 are strikingly 
conserved (5), with 11 of the 13 amino acids 
identified by NMR identical between DDR1 and 
DDR2 (14). Despite this sequence similarity, the 
two receptors bind collagen with different 
specificities: DDR1 binds to the basement 
membrane collagen IV, but DDR2 does not 
recognise this ligand (1,2,5); DDR2 binds 
collagens II and X with much higher affinity 
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than DDR1 (3,4); both DDRs bind collagen I 
with similar high-affinity (5). Regarding the 
latter activity, our preliminary experiments have 
shown that DDR1 binding to collagen I can be 
competed with excess DDR2 (data not shown), 
indicating that the DDRs might have 
overlapping binding sites on collagen I. Based 
on the sequence conservation of the DDR2 loops 
that are critical for collagen I binding, we 
suggest that the DDRs recognise similar 
collagen sequences, but that they bind these 
motifs in slightly different ways. 
We found that triple-helical DDR2-binding 
peptides not only blocked DDR2 binding to 
collagen II, but were specific agonists for the 
receptor. As these activating peptides are single 
triple helices in solution, it follows that the 
higher-order organisation of collagen into fibrils 
or fibres is not required for DDR2 activation. 
These findings may offer a possible solution to 
the conundrum of DDR regulation, given the 
abundance of collagen fibrils and fibres in 
tissues in which the DDRs are expressed: the 
receptors may be sensitive only to single triple 
helices, and not to fibrils or fibres. Single triple 
helices may be more exposed in disease states or 
during tissue remodelling, and the DDRs have 
indeed been found to be involved in tissue 
remodelling, such as wound healing (11), cancer 
invasion (28,29) or fibrosis (7,30,31). However, 
it remains to be established whether the DDRs 
can be activated by intact collagen fibrils or 
fibers. In contrast to the DDRs, the activation of 
other collagen receptors is known to require 
higher-order collagen structure. For example, 
GpVI, which recognises the peptide CRP [GPC-
(GPO)10-GPC-NH2], can only be activated after 
peptide cross-linking to introduce polymeric 
structures (24). This implies a different 
mechanism of signalling in DDR2 than in GpVI: 
the latter appears to require a multivalent ligand 
that can induce receptor clustering to signal, 
although the receptor will recognise and adhere 
to monomeric ligands (21). The same property 
has been reported for another immunoglobulin 
superfamily collagen receptor, LAIR-1 (32). 
The mechanism of DDR activation also 
differs from that of canonical RTKs, which are 
thought to be activated by ligand-induced 
dimerisation (33). In contrast to these receptors, 
the DDRs are predimerised at the cell membrane 
in the absence of ligand, and collagen binding is 
predicted to lead to a conformational change 
within the DDR dimer (34). The ~1000-fold 
difference in collagen affinity between 
monomeric (14) and dimerised DS domain (5) 
argues against two independent collagen binding 
sites, and the signalling complex may consist of 
one triple helix per DDR dimer. The collagen 
binding trench on the DS domain is rather 
shallow and would leave part of the triple helix 
available for recognition by a second DS 
domain. Since the DDR dimer is likely to have 
two-fold rotational symmetry, and a collagen 
triple helix is lacking such symmetry, the DS 
domain would have to be able to accommodate 
the triple helix in both directions. In this regard, 
we are intrigued by the absence of features in the 
DDR2-binding collagen motif imparting a strong 
directionality (see above). Perhaps, what is being 
recognised by the DDRs is the rare 
concentration of large hydrophobic side chains, 
which is found on opposite faces of the 
GVMGFO triple helix (Figure 8). 
In summary, our comprehensive analysis of 
DDR2 binding sites in human collagen II has 
identified three high-affinity binding sites, which 
are distinct from integrin and GpVI interaction 
sites. One of these binding sites is conserved 
between the α1 chains of collagens I, II and III, 
and overlaps, but is not identical, with the 
previously identified binding motif for VWF in 
collagen III. High-affinity peptides comprising 
the DDR2 binding site activated the receptor in a 
conformation-dependent manner, suggesting 
new mechanisms of receptor signalling and 
offering a new perspective on DDR activation in 
vivo. The specific DDR2-binding collagen 
sequence described here will be an invaluable 
tool for further studies into DDR function.
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FIGURE LEGENDS 
 
Figure 1. Identification of DDR2 binding sites on collagen II. Binding of recombinant DDR2 
extracellular domain proteins to immobilised collagen II Toolkit peptides in a solid phase binding 
assay. Recombinant DDR2 proteins were added for three hours at room temperature to 96 wells 
coated with collagen or peptides at 10 µg/ml. Bound proteins were detected with antibodies and 
measured as absorbance at 492 nm. (A) Binding of DDR2 extracellular domain, His-DDR2, added at 
10 µg/ml (142 nM). (B) Binding of DDR2 DS domain protein, DS2-Fc, added at 10 µg/ml (159 nM). 
Shown are the mean +/- SD of three independent experiments, each performed in triplicates. CII: 
bovine collagen II; CIV: human placental collagen IV, GPP and CRP: peptides as shown in 
Supplementary Table 1. 
 
Figure 2. DDR2 recognises collagen II Toolkit peptide, II-22, with high affinity. Solid phase binding 
assay with recombinant DDR2 proteins, added for three hours at room temperature to 96 wells coated 
with triple-helical collagen peptides or collagen at 10 µg/ml. (A) His-DDR2, (B) DS2-Fc binding to 
different immobilised peptides: Collagen II Toolkit peptide, II-22 (); bovine collagen II ();  
collagen II Toolkit peptide, II-44 (); collagen II Toolkit peptide, II-23 (); collagen II Toolkit 
peptide, II-13 (). Shown is a representative of five independent experiments, each performed in 
duplicates. 
 
Figure 3. Characterisation of collagen sequence required for high-affinity DDR2 binding. 
Recombinant His-DDR2 protein was added for three hours at room temperature to 96 wells coated 
with collagen-derived peptides or collagen at 10 µg/ml. (A) Binding of His-DDR2 to collagen III 
Toolkit peptide, III-23, and truncated peptides derived from this sequence (Table 1). (B) Binding of 
His-DDR2 to alanine-substituted peptides derived from collagen III Toolkit peptide, III-23 (Table 1). 
CII, full length bovine collagen II. Shown are the mean +/- SD of three independent experiments, 
each performed in triplicates. Black bars, His-DDR2 added at 10 µg/ml (142 nM); grey bars, His-
DDR2 added at 2 µg/ml (28 nM). 
 
Figure 4. High affinity DDR2 binding peptides block DDR2 binding to collagen II. His-DDR2 was 
added at 43 nM for three hours to 96 wells coated with 10 µg/ml bovine collagen II in the presence or 
absence of different concentrations of non-helical or triple-helical collagen peptides: non-helical 
peptide GPC-(GAP)5-GPRGQOGVMGFO-(GAP)5GPC-NH2 (); triple-helical peptide GPC-(GPP)5-
GPRGQOGVMGFO-(GPP)5-GPC-NH2 (); triple-helical peptide GPC-(GPP)5-
GPSGPRGQOGVMGFO-(GPP)5-GPC-NH2 (). Shown is the mean +/- SD of three independent 
experiments, each performed in triplicates, normalised to His-DDR2 binding in the absence of 
peptides, which was set to an absorbance of 1.0. 
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Figure 5. DDR2 binding peptides mediate autophosphorylation of cell surface DDR2. Full length 
DDR2 was transiently expressed in HEK293 cells. After stimulation for 90 min with collagen at 10 
µg/ml or collagen peptides at 100 µg/ml, cell lysates were analysed by SDS-PAGE and Western 
blotting. CI, rat tail collagen I; CII, bovine collagen II; peptide names refer to Table 1. The blot was 
probed with anti-phosphotyrosine mAb 4G10 (upper panel), followed by stripping and reprobing with 
anti-DDR2 (lower panel). The position of molecular weight markers (in kDa) are indicated. The 
experiment was carried out four times with very similar results. 
 
Figure 6. DDR2 activating peptide induces receptor phosphorylation with the same slow kinetics as 
full-length collagen. Full length DDR2 was transiently expressed in HEK293 cells. Cells were 
stimulated with either rat tail collagen I or triple-helical peptide GPC-(GPP)5-GPRGQOGVMGFO-
(GPP)5-GPC-NH2 for the indicated amounts of time (minutes). Cell lysates were analysed by SDS-
PAGE and Western blotting. The blot was probed with anti-phosphotyrosine mAb 4G10 (upper 
panel), followed by stripping and reprobing with anti-DDR2 (lower panel). The position of molecular 
weight markers (in kDa) are indicated. The experiment was carried out three times with very similar 
results.   
 
Figure 7. Alignment of human collagen sequences corresponding to collagen II Toolkit peptides II-13, 
II-22/23 and II-44. CI; CII; CIII: α1 chains of collagens I, II and III. Amino acids important in DDR2 
(*) and VWF (º) recognition sites in collagen III are marked. 
 
Figure 8. Molecular structures of the DDR2 DS domain and its binding site on collagen II. The 
structure of the DS domain (14) is shown as a surface representation, with residues implicated in 
collagen binding coloured and labelled (red, acidic residues; blue, basic residues; cyan, polar residues; 
green, hydrophobic residues). The collagen triple helix is shown with its three constituent chains 
distinguished by colouring (yellow, leading chain; orange, middle chain; red, trailing chain; chains are 
defined as in (18). Side chains important for DDR2 binding are shown as stick models and are 
labelled. The side chain conformation of the phenylalanine (F) is restricted to a single rotamer by the 
collagen structure; other side chains have been modelled to be energetically favourable. The 
hydrophobic ring around the collagen helix is indicated by square brackets and proposed to bind in the 
hydrophobic depression lined by DS residues W52, C73, N175 and C177 (see text). 
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Table 1 
Guest sequences of peptides used to characterise DDR2-collagen interaction1    
     
            
Peptide Name Sequence DDR2 binding 
   II-22 GAOGEDGROGPOGPQGARGQOGVMGFO + 
II-23 GQOGVMGFOGPKGANGEOGKAGEKGLO  + 
III-23 GPOGPSGPRGQOGVMGFOGPKGNDGAO + 
GPS-GFO    GPSGPRGQOGVMGFO + 
GPS-GVM    GPSGPRGQOGVM - 
GPS-GQO    GPSGPRGQO - 
GFOGPK                GFOGPK  - 
GPR-GPK       GPRGQOGVMGFOGPK + 
GPR-GFO       GPRGQOGVMGFO + 
GQO-GFO          GQOGVMGFO +/- 
GVMGFO             GVMGFO +/- 
   GAP-GPR-GFO2  (GAP)5-GPRGQOGVMGFO-(GAP)5 -    GFOGER GFOGER - 
   GPS-GFO-5A    GPSGARGQOGVMGFO + 
GPS-GFO-6A    GPSGPAGQOGVMGFO +/- 
GPS-GFO-8     GPSGPRGAOGVMGFO + 
GPS-GFO-9A    GPSGPRGQAGVMGFO + 
GPS-GFO-11A    GPSGPRGQOGAMGFO + 
GPS-GFO-12A     GPSGPRGQOGVAGFO - 
GPS-GFO-14A    GPSGPRGQOGVMGAO - 
GPS-GFO-15A     GPSGPRGQOGVMGFA +/- 
   CI-alpha1       GARGQAGVMGFO + 
CI-alpha2        GARGEOGNIGFO - 
   
                      
 
             
            
 
        
 
 
 
 
 
 
 
 
 
                                            
1 DDR2 binding, denotes binding to His-DDR2 or DS2-Fc. A plus sign (+) indicates a response similar 
to peptides II-22, III-23 or GPS-GFO (control); a minus sign (-) indicates less than 20% of control; +/- 
indicates 20-80% of control. 
2 GAP-GPRGFO: non-helical peptide flanked by (GAP)5 instead of (GPP)5 flanking all other peptides.  
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